<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antithrombotic effect of the synthetic thrombin inhibitor (2R,4R)-4-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1-[N2-(3-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1,2,3,4-tetrahydro-8-quinolinesulfon yl)-<z:chebi fb="0" ids="29952,32684">L-arginyl</z:chebi>]-2-piperidinecarboxylic acid monohydrate (argatroban) was investigated in cerebral vessels of the rat </plain></SENT>
<SENT sid="1" pm="."><plain>An occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was formed in pial vessels using a He-Ne laser in a closed cranial window technique </plain></SENT>
<SENT sid="2" pm="."><plain>Argatroban retarded the formation of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in a dose-dependent manner </plain></SENT>
<SENT sid="3" pm="."><plain>The antithrombotic effect of a single intravenous dose of argatroban at 0.5 mg/kg was diminished after 30 min in arterioles and after 50 min in venules, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The antithrombotic activity was maintained, however, by continuous intravenous infusion (2 mg/kg/h) </plain></SENT>
</text></document>